FAQ: What is the Effect of Guselkumab on Structural Damage in PsA?

In this episode, Wendy Simmons, PA-C from Carolina Arthritis in Wilmington, North Carolina, shares insights from nearly three decades of rheumatology experience to answer an important clinical question. Drawing on the pivotal APEX trial, recently presented at EULAR Congress 2025, Wendy reviews how guselkumab demonstrated inhibition of radiographic progression in PsA patients. Using modified vdH-S scores to assess joint space narrowing and bone erosion, the study showed that patients treated with guselkumab experienced significantly lower rates of structural joint damage compared to placebo. With ACR20 response achieved at week 24 and radiographic outcomes confirming long-term benefit, this trial reinforces the role of guselkumab as an effective therapy for psoriatic arthritis beyond symptom control. For clinicians seeking the latest data on PsA treatment and disease-modifying strategies, this discussion highlights key findings that support improved patient outcomes. For more information and additional resources, visit the RhAPP website.